Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

Giuseppe Salemi, Giovanni Savettieri, Di Costanzo, Dinacci, Vincenzo Brescia Bresciamorra, Paola Valentino, Simona Bonavita, Simone, Giuseppe Orefice, Paolo Livrea, Patti, Aldo Quattrone, Gioacchino Tedeschi, Luigi Lavorgna, Paciello, Gabriella Coniglio

Risultato della ricerca: Article

6 Citazioni (Scopus)

Abstract

This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up period, patients receiving the higher dose of Rebif were more likely to remain free from relapses [odds ratio (OR) = 2.23] and from developing both new T2 (OR = 0.15) and new T1 black hole lesions (OR = 0.22), when compared with patients in the Avonex group. Despite some limitations in the trial design, the results from this follow-up study provide helpful clinical and MRI data on the efficacy of interferon beta regimens in MS patients treated in the clinical setting.
Lingua originaleEnglish
pagine (da-a)365-368
Numero di pagine4
RivistaNeurological Sciences
Volume27 (Suppl 5)
Stato di pubblicazionePublished - 2006

Fingerprint

Interferon-beta
Italy
Multiple Sclerosis
Magnetic Resonance Imaging
Odds Ratio
Therapeutics
Interferon beta-1a
Recurrence

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cita questo

Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project. / Salemi, Giuseppe; Savettieri, Giovanni; Di Costanzo; Dinacci; Bresciamorra, Vincenzo Brescia; Valentino, Paola; Bonavita, Simona; Simone; Orefice, Giuseppe; Livrea, Paolo; Patti; Quattrone, Aldo; Tedeschi, Gioacchino; Lavorgna, Luigi; Paciello; Coniglio, Gabriella.

In: Neurological Sciences, Vol. 27 (Suppl 5), 2006, pag. 365-368.

Risultato della ricerca: Article

Salemi, G, Savettieri, G, Di Costanzo, Dinacci, Bresciamorra, VB, Valentino, P, Bonavita, S, Simone, Orefice, G, Livrea, P, Patti, Quattrone, A, Tedeschi, G, Lavorgna, L, Paciello & Coniglio, G 2006, 'Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.', Neurological Sciences, vol. 27 (Suppl 5), pagg. 365-368.
Salemi, Giuseppe ; Savettieri, Giovanni ; Di Costanzo ; Dinacci ; Bresciamorra, Vincenzo Brescia ; Valentino, Paola ; Bonavita, Simona ; Simone ; Orefice, Giuseppe ; Livrea, Paolo ; Patti ; Quattrone, Aldo ; Tedeschi, Gioacchino ; Lavorgna, Luigi ; Paciello ; Coniglio, Gabriella. / Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project. In: Neurological Sciences. 2006 ; Vol. 27 (Suppl 5). pagg. 365-368.
@article{0600086875544553ae197b3cc3c181b7,
title = "Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.",
abstract = "This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up period, patients receiving the higher dose of Rebif were more likely to remain free from relapses [odds ratio (OR) = 2.23] and from developing both new T2 (OR = 0.15) and new T1 black hole lesions (OR = 0.22), when compared with patients in the Avonex group. Despite some limitations in the trial design, the results from this follow-up study provide helpful clinical and MRI data on the efficacy of interferon beta regimens in MS patients treated in the clinical setting.",
author = "Giuseppe Salemi and Giovanni Savettieri and {Di Costanzo} and Dinacci and Bresciamorra, {Vincenzo Brescia} and Paola Valentino and Simona Bonavita and Simone and Giuseppe Orefice and Paolo Livrea and Patti and Aldo Quattrone and Gioacchino Tedeschi and Luigi Lavorgna and Paciello and Gabriella Coniglio",
year = "2006",
language = "English",
volume = "27 (Suppl 5)",
pages = "365--368",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

AU - Salemi, Giuseppe

AU - Savettieri, Giovanni

AU - Di Costanzo, null

AU - Dinacci, null

AU - Bresciamorra, Vincenzo Brescia

AU - Valentino, Paola

AU - Bonavita, Simona

AU - Simone, null

AU - Orefice, Giuseppe

AU - Livrea, Paolo

AU - Patti, null

AU - Quattrone, Aldo

AU - Tedeschi, Gioacchino

AU - Lavorgna, Luigi

AU - Paciello, null

AU - Coniglio, Gabriella

PY - 2006

Y1 - 2006

N2 - This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up period, patients receiving the higher dose of Rebif were more likely to remain free from relapses [odds ratio (OR) = 2.23] and from developing both new T2 (OR = 0.15) and new T1 black hole lesions (OR = 0.22), when compared with patients in the Avonex group. Despite some limitations in the trial design, the results from this follow-up study provide helpful clinical and MRI data on the efficacy of interferon beta regimens in MS patients treated in the clinical setting.

AB - This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up period, patients receiving the higher dose of Rebif were more likely to remain free from relapses [odds ratio (OR) = 2.23] and from developing both new T2 (OR = 0.15) and new T1 black hole lesions (OR = 0.22), when compared with patients in the Avonex group. Despite some limitations in the trial design, the results from this follow-up study provide helpful clinical and MRI data on the efficacy of interferon beta regimens in MS patients treated in the clinical setting.

UR - http://hdl.handle.net/10447/20490

M3 - Article

VL - 27 (Suppl 5)

SP - 365

EP - 368

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -